SciTech Development, LLC is a clinical stage, specialty pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SciTech Drug Delivery Platform, SDP) that maximizes the bioavailability of water-insoluble therapeutics while maintaining or improving drug safety profiles. SciTech's SDP combined with fenretinide has led to its lead drug candidate ST-001 nanoFenretinide which is targeted for several cancer indications.